Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 195 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In... April 16, 2025 An integral part of research September 21, 2022 FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab... August 5, 2026 Giving Myself the Most Time and Best Chance at Beating Cancer:... October 10, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Poherdy Lung cancer screening can’t leave anyone in the UK behind Building a Support Community During Cancer: “Your Stories” Podcast Researchers Find a Way to Prevent Cancer Cells from Taking in...
